Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrier

Jianqin Lu1, Wenchen Zhao, Yixian Huang

  • 1Center for Pharmacogenetics, ‡Department of Pharmaceutical Sciences, School of Pharmacy, and §University of Pittsburgh Cancer Institute, University of Pittsburgh , Pittsburgh, Pennsylvania 15261, United States.

Molecular Pharmaceutics
|September 30, 2014
PubMed

Insights

This study developed folic acid-decorated PEG5K-embelin2 (FA-PEG5K-EB2) nanomicelles for enhanced doxorubicin (DOX) delivery. FA-PEG5K-EB2 micelles improved DOX tumor targeting, reduced toxicity, and boosted anti-cancer efficacy.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background:

  • Doxorubicin (DOX) is a vital chemotherapeutic agent, but its use is limited by severe side effects.
  • Nanosized drug carriers offer a strategy for selective DOX delivery to tumors, potentially mitigating toxicity.
  • Previous work established PEG5K-embelin2 (PEG5K-EB2) as a dual-functional nanomicellar carrier for paclitaxel delivery.

Purpose of the Study:

  • To evaluate the efficacy of PEG5K-EB2 nanomicelles for doxorubicin (DOX) delivery.
  • To enhance DOX tumor targeting and therapeutic effects by conjugating folic acid (FA) to create FA-PEG5K-EB2 micelles.
  • To assess the safety, pharmacokinetics, and anti-tumor activity of these novel DOX-loaded nanocarriers.

Main Methods:

  • Synthesis and characterization of DOX-loaded PEG5K-EB2 and FA-PEG5K-EB2 nanomicelles.
  • In vitro evaluation of DOX loading efficiency, release kinetics, and cellular uptake in cancer and drug-resistant cell lines.
  • In vivo studies including maximum tolerated dose, pharmacokinetic profiling, biodistribution, and anti-tumor efficacy assessment in a mouse model.

Main Results:

  • DOX-loaded FA-PEG5K-EB2 micelles exhibited high loading efficiency and sustained DOX release.
  • FA-PEG5K-EB2 significantly enhanced intracellular DOX uptake in cancer cells compared to free DOX and Doxil.
  • In vivo studies demonstrated prolonged circulation, preferential tumor accumulation, increased maximum tolerated dose, and superior tumor growth inhibition with minimal toxicity for FA-PEG5K-EB2 micelles.

Conclusions:

  • FA-PEG5K-EB2 nanomicelles represent a promising drug delivery system for doxorubicin.
  • The folic acid decoration effectively improves DOX's tumor-targeting capability and therapeutic index.
  • This novel nanocarrier system warrants further investigation for clinical translation in cancer therapy.

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
160
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
148
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
6.9K